Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Loumaye

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Reproductive Medicine|August 8, 2014
Recombinant human luteinizing hormone to trigger ovulation: randomized, controlled, dose-finding pilot study in ovulation inductionRoger A Pierson, Olufemi A Olatunbosun, Donna R Chizen, et al.
Reproductive Biomedicine Online|April 5, 2003
Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparationJean-Noel Hugues, David H Barlow, Zev Rosenwaks, et al.
Journal of Clinical Medicine|December 24, 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of AdministrationJacques Donnez, Olivier Donnez, Jean Tourniaire, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2003
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatmentNicole G M Beckers, Nicholas S Macklon, Marinus J Eijkemans, et al.
The New England Journal of Medicine|February 3, 2012
Ulipristal acetate versus leuprolide acetate for uterine fibroidsJacques Donnez, Janusz Tomaszewski, Francisco Vázquez, et al.
Fertility and Sterility|March 18, 2014
Long-term treatment of uterine fibroids with ulipristal acetate ☆Jacques Donnez, Francisco Vázquez, Janusz Tomaszewski, et al.
The New England Journal of Medicine|February 3, 2012
Ulipristal acetate versus placebo for fibroid treatment before surgeryJacques Donnez, Tetyana F Tatarchuk, Philippe Bouchard, et al.
Fertility and Sterility|October 20, 2015
Long-term medical management of uterine fibroids with ulipristal acetateJacques Donnez, Olivier Donnez, Dace Matule, et al.
Lancet (London, England)|September 18, 2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trialsJacques Donnez, Hugh S Taylor, Elizabeth A Stewart, et al.
Fertility and Sterility|December 28, 2014
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroidsJacques Donnez, Robert Hudecek, Olivier Donnez, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Reproductive Medicine|August 8, 2014
Recombinant human luteinizing hormone to trigger ovulation: randomized, controlled, dose-finding pilot study in ovulation inductionRoger A Pierson, Olufemi A Olatunbosun, Donna R Chizen, et al.
Reproductive Biomedicine Online|April 5, 2003
Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method for calibrating the therapeutic preparationJean-Noel Hugues, David H Barlow, Zev Rosenwaks, et al.
Journal of Clinical Medicine|December 24, 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of AdministrationJacques Donnez, Olivier Donnez, Jean Tourniaire, et al.
The Journal of Clinical Endocrinology and Metabolism|September 13, 2003
Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatmentNicole G M Beckers, Nicholas S Macklon, Marinus J Eijkemans, et al.
The New England Journal of Medicine|February 3, 2012
Ulipristal acetate versus leuprolide acetate for uterine fibroidsJacques Donnez, Janusz Tomaszewski, Francisco Vázquez, et al.
Fertility and Sterility|March 18, 2014
Long-term treatment of uterine fibroids with ulipristal acetate ☆Jacques Donnez, Francisco Vázquez, Janusz Tomaszewski, et al.
The New England Journal of Medicine|February 3, 2012
Ulipristal acetate versus placebo for fibroid treatment before surgeryJacques Donnez, Tetyana F Tatarchuk, Philippe Bouchard, et al.
Fertility and Sterility|October 20, 2015
Long-term medical management of uterine fibroids with ulipristal acetateJacques Donnez, Olivier Donnez, Dace Matule, et al.
Lancet (London, England)|September 18, 2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trialsJacques Donnez, Hugh S Taylor, Elizabeth A Stewart, et al.
Fertility and Sterility|December 28, 2014
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroidsJacques Donnez, Robert Hudecek, Olivier Donnez, et al.
Pageof 2